Extrapolated Biosimilar Indications Won't Get More US Post-Marketing Requirements
This article was originally published in PharmAsia News
Executive Summary
Biosimilars will have the same pharmacovigilance expectations as innovator biologics in the US despite the lack of clinical data for some extrapolated indications.